Rivus Pharmaceuticals, Inc.

Although GLP-1 agonists for obesity have made a significant difference for patients and brought in a financial windfall for their manufacturers, there remains a lingering problem of the drugs reducing

By 2040, over half a billion people could be taking GLP-1 agonists or other weight loss medicines, according to McKinsey. A market that barely existed prior to 2021 could be worth over $100bn by 2030

[Editor's note: This article has been updated to clarify the primary endpoint data and incorporate comments from Rivus.] With the first round of obesity therapy having essentially been won by Novo N

While incretin drugs work nicely in a variety of metabolic disorders, many experts inside and outside the biopharma industry are exercised about one of their apparent drawbacks: the risk of loss of mu